Linden Thomas Advisory Services’s Blueprint Medicines BPMC Stock Holding History

Linden Thomas Advisory Services’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,985	Closed	-$254K	–	486
2025 Q2	$254K	Buy	+1,985	New	+$206K	0.03%	432
2023 Q3	–	Sell	-17,212	Closed	-$1.09M	–	391
2023 Q2	$1.09M	Buy	17,212 +293	+2%	+$15.9K	0.24%	174
2023 Q1	$761K	Buy	16,919 +1,021	+6%	+$46K	0.19%	219
2022 Q4	$696K	Buy	+15,898	New	+$762K	0.2%	207

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Linden Thomas Advisory Services's BPMC Position: Q3 2025 in Review

Linden Thomas Advisory Services sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 1,985 shares — an estimated $254K sold.

Linden Thomas Advisory Services first reported a position in BPMC in Q4 2022 and held it in 4 quarters. The position peaked at $1.09M in Q2 2023. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Linden Thomas Advisory Services reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Linden Thomas Advisory Services sold 1,985 Blueprint Medicines shares in Q3 2025, an estimated $254K.
Linden Thomas Advisory Services first reported a position in Blueprint Medicines in Q4 2022 and held it in 4 quarters.
Linden Thomas Advisory Services's Blueprint Medicines position peaked at $1.09M in Q2 2023.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Linden Thomas Advisory Services's 13F filing for Q3 2025, filed 6 Nov 2025.